Galantamine Tablet, Film Coated
Product Images NDC 71335-2766

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Galantamine (NDC 71335-2766). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Figure 1: Time-course Of The Change From Baseline In Adas-cog Score For Patients Completing 21 Weeks (5 Months) Of Treatment (Galantamine Fig1)

Figure 1: Time-course Of The Change From Baseline In Adas-cog Score For Patients Completing 21 Weeks (5 Months) Of Treatment (Galantamine Fig1)
A line graph showing the mean change from baseline in ADAS-cog score over 21 weeks of treatment, comparing placebo and three dosage levels of galantamine (8 mg/day, 16 mg/day, 24 mg/day). The graph indicates improvement as a negative change and decline as positive change in scores.*
FDA Label Image

Figure 10: Time-course Of The Change From Baseline In Adas-cog Score For Patients Completing 13 Weeks Of Treatment (Galantamine Fig10)

Figure 10: Time-course Of The Change From Baseline In Adas-cog Score For Patients Completing 13 Weeks Of Treatment (Galantamine Fig10)
A line graph showing mean change from baseline in ADAS-cog score over 13 weeks of treatment. It compares placebo and Galantamine 24 or 32 mg/day groups. The graph indicates improvement for the Galantamine group and minimal change or decline for the placebo group over the treatment period.*
FDA Label Image

Figure 11: Cumulative Percentage Of Patients Completing 13 Weeks Of Double-blind Treatment With Specified Changes From Baseline In Adas-cog Scores. The Percentages Of Randomized Patients Who Completed The Study Were: Placebo 90%, 24 To 32 mg/day 67%. (Galantamine Fig11)

Figure 11: Cumulative Percentage Of Patients Completing 13 Weeks Of Double-blind Treatment With Specified Changes From Baseline In Adas-cog Scores. The Percentages Of Randomized Patients Who Completed The Study Were: Placebo 90%, 24 To 32 mg/day 67%. (Galantamine Fig11)
A cumulative percentage graph comparing ADAS-cog (Alzheimer's Disease Assessment Scale-cognitive subscale) change from baseline between placebo and 24 or 32 mg/day Galantamine dosage groups. The x-axis shows ADAS-cog change values ranging from -15 to 15, while the y-axis shows cumulative percentage of patients from 0 to 100%. Two curves represent placebo (open circles) and treatment (black diamonds) groups, illustrating their comparative cognitive changes over time.*
FDA Label Image

Figure 12 (Galantamine Fig12)

Figure 12 (Galantamine Fig12)
A bar chart comparing the percentage of patients rated by CIBIC-plus categories for placebo versus 24 or 32 mg/day doses of Galantamine. The x-axis shows CIBIC-plus Ratings from Markedly Improved to Markedly Worse, and the y-axis shows the percentage of patients. Bars illustrate differences between placebo and active treatment groups across each rating.*
FDA Label Image

Figure 2: Cumulative Percentage Of Patients Completing 21 Weeks Of Double-blind Treatment With Specified Changes From Baseline In Adas-cog Scores. The Percentages Of Randomized Patients Who Completed The Study Were: Placebo 84%, 8 mg/day 77%, 16 mg/day 78% And 24 mg/day 78%. (Galantamine Fig2)

Figure 2: Cumulative Percentage Of Patients Completing 21 Weeks Of Double-blind Treatment With Specified Changes From Baseline In Adas-cog Scores. The Percentages Of Randomized Patients Who Completed The Study Were: Placebo 84%, 8 mg/day 77%, 16 mg/day 78% And 24 mg/day 78%. (Galantamine Fig2)
A cumulative percentage plot showing ADAS-cog (Alzheimer's Disease Assessment Scale-cognitive subscale) change from baseline in patients. The graph compares placebo and three dosage groups of Galantamine (8 mg/day, 16 mg/day, and 24 mg/day) with changes ranging from -15 to +15 on the x-axis and cumulative percentage from 0 to 100% on the y-axis.*
FDA Label Image

Figure 3: Distribution Of Cibic-plus Ratings At Week 21 (Galantamine Fig3)

Figure 3: Distribution Of Cibic-plus Ratings At Week 21 (Galantamine Fig3)
A bar chart displaying the percentage of patients by CIBIC-plus rating categories for different treatment groups: placebo, 8 mg/day, 16 mg/day, and 24 mg/day. The x-axis lists ratings from markedly improved to markedly worse, while the y-axis shows percentage of patients. The chart compares patient outcomes across these dosing groups.*
FDA Label Image

Figure 4: Time-course Of The Change From Baseline In Adas-cog Score For Patients Completing 26 Weeks Of Treatment (Galantamine Fig4)

Figure 4: Time-course Of The Change From Baseline In Adas-cog Score For Patients Completing 26 Weeks Of Treatment (Galantamine Fig4)
A line graph showing mean change from baseline in ADAS-cog score over 26 weeks of treatment. The graph compares three groups: placebo, 24 mg/day, and 32 mg/day doses, illustrating cognitive improvement or decline at weeks 3, 13, and 26. Error bars indicate standard error.*
FDA Label Image

Figure 5 (Galantamine Fig5)

Figure 5 (Galantamine Fig5)
A cumulative percentage plot showing patient distribution by ADAS-cog change from baseline for Galantamine treatment groups (24 mg/day and 32 mg/day) compared to placebo. The x-axis represents ADAS-cog change, and the y-axis shows cumulative percentage of patients. The graph illustrates cognitive change with markers for placebo, 24 mg/day, and 32 mg/day doses.*
FDA Label Image

Figure 6: Distribution Of Cibic-plus Ratings At Week 26 (Galantamine Fig6)

Figure 6: Distribution Of Cibic-plus Ratings At Week 26 (Galantamine Fig6)
A bar chart illustrating the CIBIC-plus rating outcomes for three groups of patients receiving either placebo, 24 mg/day, or 32 mg/day dosages. The Y-axis represents the percentage of patients, while categories on the X-axis include Markedly Improved, Moderately Improved, Minimally Improved, No Change, Minimally Worse, Moderately Worse, and Markedly Worse. The chart compares patient response distributions across these rating categories.*
FDA Label Image

Figure 7: Time-course Of The Change From Baseline In Adas-cog Score For Patients Completing 26 Weeks Of Treatment (Galantamine Fig7)

Figure 7: Time-course Of The Change From Baseline In Adas-cog Score For Patients Completing 26 Weeks Of Treatment (Galantamine Fig7)
A line graph depicting mean change from baseline in ADAS-cog score over 26 weeks of treatment. The graph compares placebo, 24 mg/day, and 32 mg/day doses, showing improvement or decline trends across weeks 0, 3, 13, and 26.*
FDA Label Image

Figure 8: Cumulative Percentage Of Patients Completing 26 Weeks Of Double-blind Treatment With Specified Changes From Baseline In Adas-cog Scores. The Percentages Of Randomized Patients Who Completed The Study Were: Placebo 87%, 24 mg/day 80%, And 32 mg/day 75%. (Galantamine Fig8)

Figure 8: Cumulative Percentage Of Patients Completing 26 Weeks Of Double-blind Treatment With Specified Changes From Baseline In Adas-cog Scores. The Percentages Of Randomized Patients Who Completed The Study Were: Placebo 87%, 24 mg/day 80%, And 32 mg/day 75%. (Galantamine Fig8)
A line graph showing cumulative percentage of patients versus ADAS-cog change from baseline. It compares three treatments: placebo, 24 mg/day, and 32 mg/day of galantamine. Vertical markers indicate points of -10, -7, -4, and no change in ADAS-cog score.*
FDA Label Image

Figure 9: Distribution Of Cibic-plus Rating At Week 26 (Galantamine Fig9)

Figure 9: Distribution Of Cibic-plus Rating At Week 26 (Galantamine Fig9)
A bar chart displaying the percentage of patients in various Clinical Global Impression of Change (CGIC)-plus rating categories comparing Placebo, 24 mg/day, and 32 mg/day dosage groups. The x-axis shows categories from Markedly Improved to Markedly Worse, while the y-axis shows the percentage of patients from 0 to 60%. The chart compares treatment effects on patient condition changes.*
FDA Label Image

Chemical Structure (Galantamine Str)

Chemical Structure (Galantamine Str)
Chemical structure diagram of Galantamine illustrating its molecular framework including rings, oxygen, nitrogen, and hydrogen atoms. The structure also indicates the presence of a hydrobromide (HBr) component.*
FDA Label Image

Label (Lbl713352766)

Label (Lbl713352766)
Label for Galantamine Tablets, USP 4 mg film-coated tablets, repackaged by Bryant Ranch Prepack and manufactured by Aurobindo Pharma Limited. The label indicates a package size of 60 tablets and includes storage instructions along with QR codes for product information and usual dosage details.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.